Rare Cancer Clinical Trials

5 recruitingLast updated: May 5, 2026

There are 9 actively recruiting rare cancer clinical trials across 15 countries. Studies span Not Applicable, Phase 2, Phase 4. Top locations include Toronto, Ontario, Canada, Heidelberg, Germany, Bethesda, Maryland, United States. Updated daily from ClinicalTrials.gov.


Rare Cancer Trials at a Glance

9 actively recruiting trials for rare cancer are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Not Applicable with 1 trial, with the heaviest enrollment activity in Toronto, Heidelberg, and Bethesda. Lead sponsors running rare cancer studies include University Health Network, Toronto, National Cancer Institute (NCI), and Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS.

Browse rare cancer trials by phase

Treatments under study

About Rare Cancer Clinical Trials

Looking for clinical trials for Rare Cancer? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Rare Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Rare Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

Solid TumorOther Solid TumorsVery Rare Tumors+2 more
National Cancer Institute (NCI)4,000 enrolled1 locationNCT07489378
Recruiting

Registry Study on Rare Cancers in Korea

Rare Cancer
Yonsei University500 enrolled1 locationNCT06746766
Recruiting
Phase 4

Dabrafenib and/or Trametinib Rollover Study

MelanomaNon-small Cell Lung CancerSolid Tumor+2 more
Novartis Pharmaceuticals100 enrolled28 locationsNCT03340506
Recruiting

Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)

Breast CancerLung CancerMelanoma+7 more
University Health Network, Toronto7,000 enrolled1 locationNCT07524114
Recruiting

Molecularly Aided Stratification for Tumor Eradication Research

MultiomicsRare Cancers
German Cancer Research Center10,000 enrolled1 locationNCT05852522
Recruiting

Genomic Investigation of Unusual Responders

Breast CancerColorectal, CancerCancer+8 more
University Health Network, Toronto100 enrolled1 locationNCT03740503
Recruiting

Ontario-wide Cancer TArgeted Nucleic Acid Evaluation

Breast CancerColorectal, CancerLung Cancer+8 more
University Health Network, Toronto10,000 enrolled7 locationsNCT02906943
Recruiting
Phase 2

A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.

Soft Tissue SarcomaNeuroendocrine TumorsVaccination+2 more
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS51 enrolled1 locationNCT04166006
Recruiting
Not Applicable

TCF-001 TRACK (Target Rare Cancer Knowledge) Study

CholangiocarcinomaRare CancersCancer of Unknown Primary Site
TargetCancer Foundation400 enrolled1 locationNCT04504604